(Dallas, TX. – October 5, 2011) StockGuru Shines its Spotlight on PLC Systems Inc. (OTCBB: PLCSF), a company focused on innovative medical device technologies. The Company announced yesterday that it had signed an agreement with ACIST Medical Systems, Inc., a Bracco Group company, to distribute its innovative RenalGuard System™ in France and Germany. The Company closed on October 4, 2011, at $0.115, trading in a fifty-two week range of $0.24 – 0.06.
Under the terms of the agreement, ACIST will be the exclusive distributor of PLC’s RenalGuard® in the two largest countries in the European Union, expanding RenalGuard’s distribution significantly in Europe, where PLC has secured the CE Mark for its RenalGuard device. As part of the agreement, ACIST will purchase an initial stocking order of RenalGuard consoles and single use sets.
“Today’s news is a critical catalyst to enable PLC to expand the use of RenalGuard in the largest countries in Europe,” said Mark R. Tauscher, President and Chief Executive Officer of PLC Systems. “ACIST brings enormous credibility to our effort to increase the number of patients who can access RenalGuard. We’re confident that in partnership with them, we’ll be able to reach many more hospitals and healthcare institutions to allow clinicians to utilize RenalGuard to protect patients.”
Recent positive scientific data from investigator-sponsored clinical trials of RenalGuard in Europe have been presented at major international medical conferences and published in peer-reviewed journals. The results from these trials showed that RenalGuard is superior to the current standard of care in preventing Contrast-Induced Nephropathy (CIN), a potentially fatal injury to the kidney that occurs when at-risk patients undergo certain imaging procedures. More than 15% of the patients in the more than 7 million imaging procedures conducted worldwide each year are considered at-risk of acquiring CIN, based upon their age and other criteria.
The development of CIN has been found to lead to a range of serious and potentially deadly outcomes in patients who already have compromised kidney function. RenalGuard Therapy, based on the concept that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast agents, was also found in European clinical trials to significantly reduce the need for in-hospital dialysis in high risk patients.
PLC already has distribution agreements for RenalGuard in Italy, Spain, Portugal, The Netherlands, Austria, Belgium, Croatia, Luxembourg, Monaco and Switzerland in Europe, as well as in select other countries around the world. The company is finalizing preparations for its U.S. pivotal trial of RenalGuard, which is required in order to secure approval from the U.S. Food & Drug Administration to market and sell RenalGuard in the U.S.
About PLC Systems Inc.
PLC Systems Inc., headquartered in Milford, Mass., is a medical device company focused on innovative technologies for the cardiac and vascular markets. PLC’s newest product, RenalGuard, has been developed to help prevent the onset of Contrast-Induced Nephropathy (CIN) in at-risk patients undergoing certain imaging procedures. The Product is CE-marked and is being marketed in Europe and selected countries around the world. Two investigator-sponsored European studies have demonstrated RenalGuard’s effectiveness at preventing CIN. RenalGuard is being studied in a pivotal trial in the U.S., as required for approval by FDA, and has not been approved for patient use in the United States.
About ACIST Medical Systems
ACIST Medical Systems, a Bracco Group company, is a market leader in the development of innovative and advanced contrast imaging system technologies for cardiovascular and radiological applications. Since 1998, ACIST has manufactured more than 2,200 advanced, variable-flow contrast delivery systems for cardiologists in more than 45 countries. In 2011, ACIST reached a milestone with more than 10 million patients having undergone a cardiovascular angiography procedure using an ACIST Contrast Delivery System. Headquartered in Eden Prairie, Minn., with regional offices in Europe and Asia, ACIST employs more than 220 people worldwide. To learn more, visit www.acist.com.
This press release contains “forward-looking” statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn, the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments that may affect the market for our products, regulatory approval requirements that may affect the market for our products, and additional risk factors described in the “Forward Looking Statements” section of our Annual Report on Form 10-K for the year ended December 31, 2010, a copy of which is on file with the SEC.
PLC Systems, PLC Medical Systems, PLC, RenalGuard and RenalGuard Therapy are trademarks of PLC Systems Inc.
To view this StockGuru Spotlight, please visit: http://www.stockguru.com/category/latest-spotlights/
To get free alerts on this and other similar stocks, please register here:
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at email@example.com. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: firstname.lastname@example.org.
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
John Pentony, Publisher, Stockguru.com
Tel: +1 469 252 3031